Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2019 Jan 10

PMID 30621039

Citations 47

Authors

Yasuyoshi Miyata

Yohei Shida

Tomoaki Hakariya

Hideki Sakai

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most common cancer among men. Green tea consumption is reported to play an important role in the prevention of carcinogenesis in many types of malignancies, including prostate cancer; however, epidemiological studies show conflicting results regarding these anti-cancer effects. In recent years, in addition to prevention, many investigators have shown the efficacy and safety of green tea polyphenols and combination therapies with green tea extracts and anti-cancer agents in in vivo and in vitro studies. Furthermore, numerous studies have revealed the molecular mechanisms of the anti-cancer effects of green tea extracts. We believe that improved understanding of the detailed pathological roles at the molecular level is important to evaluate the prevention and treatment of prostate cancer. Therefore, in this review, we present current knowledge regarding the anti-cancer effects of green tea extracts in the prevention and treatment of prostate cancer, with a particular focus on the molecular mechanisms of action, such as influencing tumor growth, apoptosis, androgen receptor signaling, cell cycle, and various malignant behaviors. Finally, the future direction for the use of green tea extracts as treatment strategies in patients with prostate cancer is introduced.

Citing Articles

Associations between green tea drinking and body mass index, serum lipid profile and prostate-specific antigen in a Ghanaian population: a cross-sectional study.

Ntim E, Nyamekye S, Yeboah K, Safianu R, Djankpa F, Ainooson G BMC Nutr. 2025; 11(1):55.

PMID: 40087803 DOI: 10.1186/s40795-025-01039-9.

Exploring the therapeutic potential of natural products in modulating miRNA networks in prostate cancer.

Mohammed O Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976718 DOI: 10.1007/s00210-025-03898-2.

Potential Benefits of Green Tea in Prostate Cancer Prevention and Treatment: A Comprehensive Review.

Liu G, Yao Z, Chen G, Li Y, Liang B Chin J Integr Med. 2024; 30(11):1045-1055.

PMID: 38561489 DOI: 10.1007/s11655-024-4100-2.

Decaffeinated green tea polyphenols supplementation had no adverse health effects in girls with obesity: a randomized controlled trial.

Yao D, Xie L, Du K, Yao X, Shen X Asia Pac J Clin Nutr. 2024; 33(1):111-117.

PMID: 38494693 PMC: 11170002. DOI: 10.6133/apjcn.202403_33(1).0012.

A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.

Dachani S, Kaleem M, Mujtaba M, Mahajan N, Ali S, Almutairy A ACS Omega. 2024; 9(9):10030-10048.

PMID: 38463249 PMC: 10918819. DOI: 10.1021/acsomega.3c09780.

References

Kleiner D, Stetler-Stevenson W . Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999; 43 Suppl:S42-51. DOI: 10.1007/s002800051097. View

Lokeshwar B . MMP inhibition in prostate cancer. Ann N Y Acad Sci. 1999; 878:271-89. DOI: 10.1111/j.1749-6632.1999.tb07690.x. View

HANDSCHUH G, Candidus S, Luber B, Reich U, Schott C, Oswald S . Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 1999; 18(30):4301-12. DOI: 10.1038/sj.onc.1202790. View

De Marzo A, Marchi V, Epstein J, Nelson W . Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155(6):1985-92. PMC: 1866955. DOI: 10.1016/S0002-9440(10)65517-4. View

Gupta S, Ahmad N, Nieminen A, Mukhtar H . Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol. 2000; 164(1):82-90. DOI: 10.1006/taap.1999.8885. View

Ren F, Zhang S, Mitchell S, Butler R, Young C . Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 2000; 19(15):1924-32. DOI: 10.1038/sj.onc.1203511. View

Wise G, Marella V, Talluri G, Shirazian D . Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000; 164(3 Pt 1):722-5. DOI: 10.1097/00005392-200009010-00024. View

Agarwal R . Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000; 60(8):1051-9. DOI: 10.1016/s0006-2952(00)00385-3. View

Putzi M, De Marzo A . Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000; 56(5):828-32. DOI: 10.1016/s0090-4295(00)00776-7. View

10.

Yonemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K . Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res. 2000; 6(11):4234-42. View

11.

Bhatia N, Agarwal R . Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001; 46(2):98-107. DOI: 10.1002/1097-0045(20010201)46:2<98::aid-pros1013>3.0.co;2-k. View

12.

Chung L, Cheung T, Kong S, Fung K, Choy Y, Chan Z . Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci. 2001; 68(10):1207-14. DOI: 10.1016/s0024-3205(00)01020-1. View

13.

Gupta S, Hastak K, Ahmad N, Lewin J, Mukhtar H . Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A. 2001; 98(18):10350-5. PMC: 56964. DOI: 10.1073/pnas.171326098. View

14.

Heizmann C . The multifunctional S100 protein family. Methods Mol Biol. 2002; 172:69-80. DOI: 10.1385/1-59259-183-3:069. View

15.

Miyata Y, Sakai H, Hayashi T, Kanetake H . Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate. 2002; 54(2):125-32. DOI: 10.1002/pros.10175. View

16.

Gupta S, Hussain T, Mukhtar H . Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003; 410(1):177-85. DOI: 10.1016/s0003-9861(02)00668-9. View

17.

Kaplan-Lefko P, Chen T, Ittmann M, Barrios R, Ayala G, Huss W . Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003; 55(3):219-37. DOI: 10.1002/pros.10215. View

18.

Hastak K, Gupta S, Ahmad N, Agarwal M, Agarwal M, Mukhtar H . Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene. 2003; 22(31):4851-9. DOI: 10.1038/sj.onc.1206708. View

19.

Kazi A, Daniel K, Smith D, Kumar N, Dou Q . Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003; 66(6):965-76. DOI: 10.1016/s0006-2952(03)00414-3. View

20.

Hojilla C, Mohammed F, Khokha R . Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer. 2003; 89(10):1817-21. PMC: 2394437. DOI: 10.1038/sj.bjc.6601327. View